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REVIEW
Abstract: Opioid receptors are widely expressed in the central and peripheral nervous system
as well as in numerous nonneuronal tissues. Both animal models and human clinical data
support the involvement of peripheral opioid receptors in analgesia, particularly in inflammation
where both opioid receptor expression and efficacy are increased. Immune cells have been
shown to contain numerous opioid peptides such as β-endorphin (END), met-enkephalin
(ENK), and dynorphin-A (DYN), although the predominant opioid peptide involved in immune-
cell mediated antinociception is thought to be END. These opioid-containing immune cells
migrate to inflamed tissues during a complex process of recruitment by chemokines, adhesion,
and extravasation. In these tissues, opioid peptide is released from the immune cells upon
stimulation with corticotrophin-releasing factor (CRF), noradrenaline, and interleukin 1β
(IL-1β), and the immune cells return to the local lymph node depleted of peptide. Consistent
with this model, systemic immunosuppression may lead to impaired endogenous analgesia as
competent immune cells are essential to achieve release of endogenous opioid peptides within
inflamed tissue. A further level of complexity is added by the observation that exogenous
opioids may impair immune cell function, although there is some evidence to suggest that
endogenous opioid peptides do not share this immunosuppressive effect. Improving our
understanding of endogenous opioid mechanisms will provide valuable insight towards the
development of novel treatments for pain with improved side effect profiles.
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Introduction
Pain arising from inflammatory conditions is often treated with agents that inhibit
the immune response, such as corticosteroids, or modulators of the inflammatory
cascade, such as nonsteroidal antiinflammatory drugs (NSAIDs) (Dequeker 1999).
These drugs are associated with substantial adverse effects and risks with long-term
use, ranging from gastrointestinal (GI) insult to opportunistic infections, and
osteoporosis (Hirschowitz 1994; Dequeker 1999). While opioid receptor agonists
have limited or, more likely, poorly understood antiinflammatory action, they remain
useful effective analgesic agents in these conditions. However, respiratory depression,
sedation, and constipation remain as dose-limiting side effects after systemic
administration of this drug class. Tolerance, while not a common occurrence, can
develop during long-term use (Sessle and Henry 1985; Mansour et al 1988;
Marinangeli et al 2004; Jensen et al 2005).
The immune system is traditionally thought of as a contributor to inflammatory
pain. However, a new analgesic role has been described for the immune system in
the release of endogenous opioid peptides from immune cells within inflamed tissue
(Stein et al 1997). The benefit of peripheral immune-mediated opioid analgesia is
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targeted analgesia at the site of inflammation, and thus
avoidance of side effects mediated by activation of opioid
receptors in the central nervous system (CNS), or on
peripheral organs such as the GI tract. Although immune
cell-mediated endogenous opioid analgesia appears to
challenge our current understanding of the role of the
immune system in inflammation, it is likely that the two
approaches to inflammatory pain treatment are not in
contrast, but complementary. The role of the immune system
in peripheral analgesia is likely to be delicately balanced,
depending on whether the action of infiltrating cells is
proinflammatory, proalgesic, or both; either predicted by
the immune cell, or by the injury, or disease status. In
situations where endogenous antinociception exceeds
hyperalgesia mediated by immune cells, immuno-
suppression or modulation of immune cell trafficking may
increase pain (Hermanussen et al 2004).
A better understanding of the endogenous pathways and
mechanisms involved in peripheral analgesia may not only
enable us to target these pathways for novel antinociceptive
approaches and avoid systemic side effects of opioid
treatment, but it will also allow us to identify patients in
whom immunosuppression may have detrimental effects on
pain control and minimise the possible algesic effects of
immunosuppression in these patients.
Opioid receptor distribution and
mechanisms that mediate
antinociception
Since their first characterization in 1973, 3 main opioid
receptors, referred to as µ (MOR), δ (DOR), and κ (KOR),
have been defined (Pert and Snyder 1973; Simon et al 1973;
Terenius 1973; Law et al 2000). These opioid receptors can
exist as several splice variants, which are differentially
expressed in the central and peripheral nervous systems as
well as varying nonneuronal tissues, presumably due to
different messenger ribonucleic acid (mRNA) processing
as they are derived from the same gene (Abbadie et al 2000;
Law et al 2000).
Opioid receptor structure and function
Opioid receptors are prototypical G-protein coupled
receptors belonging to the subfamily of rhodopsin receptors
and consist of approximately 400 amino acids (Law et al
2000; Pil and Tytgat 2003). On a molecular basis, they
possess 7 α-helical transmembrane domains and an
extracellular N-terminus with multiple glycosylation sites
(Law et al 2000). MOR, DOR, and KOR are highly
homologous to each other at the sequence and post-
translational levels, with particularly high conservation in
the regions spanning the transmembrane domains and
intracellular loops (Knapp et al 1995; Akil et al 1996; Law
et al 2000; Pil and Tytgat 2003). Divergence can be found
at the N- and C-termini as well as the extracellular loops,
accounting for the unique pharmacological properties of
these receptors (Knapp et al 1995; Akil et al 1996; Law et
al 2000; Pil and Tytgat 2003). Opioid receptors can couple
to both pertussis toxin-sensitive and insensitive G-proteins,
with coupling characteristics differing slightly between the
receptor types. G-protein coupling of opioid receptors to
their effectors can be direct or involve intermediate or other
indirect effector pathways (Connor and Christie 1999).
Activation of inwardly rectifying K
+ channels (GIRK
+),
inhibition of voltage-dependent Ca
2+ channels as well as
inhibition of adenylyl cyclase are direct G-protein-coupled
effects of opioid receptor activation (Connor and Christie
1999; Law et al 2000). Conversely, opioid receptors can
activate phospholipase C (PLC), the mitogen-activated
protein kinase (MAPK) cascade, and large conductance
Ca2+-activated K+ channels by utilising other intermediary
messenger systems (Connor and Christie 1999; Law et al
2000). Modification of Ca2+ and K+ conductance by opioid
receptors can lead to a decrease in neuronal excitability, a
decrease in neuronal firing rate, and inhibition of
neurotransmitter release (Connor and Christie 1999; Law
et al 2000). Functionally, opioid receptors have been
implicated in regulation of pain, reinforcement, reward,
neuroendocrine modulation, and alteration in neuro-
transmitter release (Mansour et al 1995). The consequence
of opioid receptor activation appears to be correlated closely
with the anatomical location as well as expression levels of
the opioid receptor subtypes (Mansour et al 1995).
Opioid receptor expression and
function in the central nervous system
Opioid receptors are widely and differentially distributed
in the CNS. MOR, in particular, is widely distributed
throughout the forebrain, midbrain, and hindbrain with
greatest expression apparent in the neocortex, caudate-
putamen, nucleus accumbens, thalamus, hippocampus,
amygdala, and nucleus tractus solitarius (Mansour et al 1988,
1995). This distribution of the MOR is consistent with its
suggested role in pain perception as well as sensorimotor
integration. Conversely, KOR has been found to be
expressed in moderate amounts in many brain areas, withTherapeutics and Clinical Risk Management 2005:1(4) 281
Opioid analgesia and inflammation
greatest expression in the caudate putamen, nucleus
accumbens, hypothalamus, amygdala, and neural lobe of
the pituitary (Mansour et al 1988, 1995). KOR has been
implicated to be involved in feeding, pain perception, and
neuroendocrine function. DOR is particularly highly
expressed in olfactory related neural areas, the neocortex,
caudate-putamen, nucleus accumbens, and amygdala while
exhibiting limited binding in the thalamus, hypothalamus,
and brainstem (Mansour et al 1988, 1995). This distribution
corresponds with the suggested involvement of DOR in
motor as well as olfactory and cognitive functioning.
The functional consequences arising from these
expression patterns of opioid receptors may affect many
other physiological systems, which can have important
implications for the clinical use of opioids, particularly in
the unwanted side effects of systemically administered
opioid receptor agonists. Many side effects arising from
systemic administration of opioids are due to activation of
central opioid receptors. Administration of MOR agonists
has been linked to centrally mediated cardiovascular and
renal effects (Mansour et al 1988, 1995; Gutkowska et al
2004; Mao and Wang 2005). Of particular relevance to the
use of opioids as analgesics are respiratory depression
mediated though activation of MOR and DOR in the
brainstem, as well as KOR-mediated sedation; both of which
can be dose-limiting side effects of systemic treatment with
opioids (Sessle and Henry 1985; Mansour et al 1988).
Opioid receptor expression and
function in the spinal cord and
peripheral nervous system
Opioid-mediated analgesia is mediated by modulation of
ascending and descending pain pathways (Mansour et al
1988; Vaughan et al 1997; Pan et al 2004). Accordingly,
MOR, DOR, and KOR expression has been confirmed in
dorsal root ganglia, the spinal cord, and trigeminal nucleus
of the ascending pain pathway as well as the central Gray
area, pontine, gigantocellulare, and intermediate reticular
nuclei of the descending pain pathway, with predominantly
MOR and KOR expression in the median raphe and raphe
magnus (Mansour et al 1988). In the periaqueductal gray
region and the nucleus locus coeruleus, opioid receptor
agonists produce analgesia by disinhibiting descending
fibres through inhibition of Gamma-Aminobutyric acid
(GABA)-ergic neuronal inputs, which modulates other
descending pathways in turn, such as noradrenergic neurons,
to produce analgesia (Vaughan et al 1997; Pan et al 2004).
In addition to spinal and centrally mediated opioid
analgesia, opioid receptors expressed on peripheral neurons
can also contribute to antinociception. Numerous animal
models and human clinical trials in support of this peripheral
opioid analgesia have been described and will be discussed
in greater detail in the next section. While targeting these
peripheral mechanisms may provide analgesic strategies that
can avoid some or all of the central side effects of systemic
opioid agonists, some peripherally mediated side effects may
remain problematic. This is a result of opioid receptor
expression on  peripheral nervous system neurons
innervating peripheral organs such as the skin and GI tract
(Bagnol et al 1997; Fickel et al 1997; Bigliardi-Qi et al 2004;
Holzer 2004). MOR and KOR have been found to be
expressed in the stomach, duodenum, jejunum, ileum as well
as proximal and distal colon, where their function is thought
to include control of visceral pain, regulation of transit time
of luminal contents, and mucosal transport of fluids and
electrolytes (Bagnol et al 1997; Fickel et al 1997; Eastwood
and Grundy 2000; Holzer 2004; Gray et al 2005).
Accordingly, the adverse effect of systemic administration
of opioid agonists on GI function is thought to arise
primarily from modulation of the enteric pathways
governing peristalsis by opioid receptor agonists (Bagnol
et al 1997; Fickel et al 1997; Holzer 2004). The effect of
opioid receptor agonists on gut motility and secretion has
been utilised clinically in the symptomatic management of
diarrhea (Sun et al 1997). Furthermore, opioid receptors
may be involved in the modification of GI inflammation,
possibly through the protein kinase C-mediated desensitiza-
tion of chemokine receptors (Philippe et al 2003; Zhang et
al 2003).
Opioid receptor expression and
function in nonneuronal tissues
Opioid receptor protein and mRNA have also been described
in several nonneuronal tissues such as vascular and cardiac
epithelia as well as keratinocytes, although the significance
of opioid receptor expression in these nonnociceptive tissues
is less clear (Bidlack 2000; Cadet et al 2000; Mousa et al
2001; Bigliardi-Qi et al 2004). MOR, DOR, and KOR are
also expressed on various immune cells including
lymphocytes and macrophages. Activation of the receptors
have been reported to modulate immune function including
the macrophage oxidative burst and cytokine production
(Bidlack 2000). Evidence for the expression of all 3 types
of opioid receptors on immune cells stems from functional
evidence suggesting that MOR, DOR, and KOR agonistsTherapeutics and Clinical Risk Management 2005:1(4) 282
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can modulate immune cell function, and includes
immunohistochemical and binding studies which verify the
expression of MOR, DOR, and KOR on numerous immune
cells (Bidlack 2000). In addition, mRNA encoding for opioid
receptors has been obtained from immune cells and supports
the identification of opioid receptors expressed on immune
cells as identical to neuronal receptors (Bidlack 2000).
In summary, opioid receptor protein and mRNA have
been described in both central and peripheral nervous
systems as well as in several nonneuronal tissues. Activation
of these differentially distributed receptors by systemic
treatment with opioid receptor agonists not only causes
analgesia, but can be directly correlated to clinically
observed adverse effects such as respiratory depression,
sedation, and constipation (Sessle and Henry 1985; Mansour
et al 1988, 1995; Fickel et al 1997; Vaughan et al 1997;
Gutkowska et al 2004; Holzer 2004; Pan et al 2004; Mao
and Wang 2005).
Peripheral opioid receptors and
their contribution to analgesia
Including centrally mediated effects, the potential that opioid
receptors of the peripheral nervous system have for
mediating effective analgesia is well documented. Common
strategies to isolate the activation of peripheral opioid
receptors include the administration of local, systemically
inactive doses of opioids, and the use of hydrophilic opioids
that do not readily penetrate the blood-brain barrier.
Animal models
In animal models of inflammatory pain, peripheral MOR,
DOR, and KOR participate in the suppression of pain. In
the inflammatory phase of the formalin test in rats, novel
peripherally restricted µ-opioid agonists, administered
subcutaneously, produced dose-dependent antinociception
(Furst et al 2005). This effect was reversed by the
peripherally restricted antagonist naloxone methiodide,
confirming the activation of peripheral MOR (Furst et al
2005). The DOR agonist SNC80 produced dose-dependent
antinociception in PGE2-induced hyperalgesia of the rat paw
following subcutaneous administration (Pacheco and Duarte
2005). This effect was not observed after equivalent
administration at a remote site, indicating that anti-
nociception was delivered by peripheral DOR (Pacheco and
Duarte 2005). KOR-selective opioid agonists, when
administered subcutaneously to the paw, evoked potent dose-
dependent increases in pain thresholds after Freund’s
complete adjuvant (FCA)-induced chronic inflammation,
an effect antagonized by naloxone methiodide (Binder et al
2001). In an animal model of inflammatory bowel disease,
peripherally restricted κ-opioid agonists produced dose-
dependent, peripherally antagonized reductions in
visceromotor responses and afferent nerve activity,
providing further evidence that peripheral KOR effects
antinociception (Sengupta et al 1999). In a single study using
FCA-induced inflammation of the rat paw, locally acting
MOR-, DOR-, and KOR-selective agonists delivered
antinociception that was dose-dependent, stereospecific, and
reversible by receptor specific antagonists (Stein et al 1989).
In addition to inflammatory pain, peripheral opioid receptors
reportedly attenuate nociceptive responses in rats following
thermal injury (Nozaki-Taguchi and Yaksh 1999), and in
animal models of uterine cervical distension (Sandner-
Kiesling et al 2002), neuropathic pain (Pertovaara and Wei
2001; Truong et al 2003; Obara et al 2004), and nociceptive
pain (Furst et al 2005). Moreover, a technique involving
viral-driven transfer and overproduction of proenkephalin A,
a precursor for the endogenous opioid peptide enkephalin
in trigeminal ganglion neurons, resulted in long lasting
attenuation of allodynia in a rat model of neuropathic pain
(Meunier et al 2005). Immunohistochemistry indicated that
transgene-derived opioids were transported predominantly
to the peripheral ends of primary sensory neurons. The
abolition of transgene-derived antinociception by naloxone
methiodide confirms that peripheral opioid receptors were
responsible for the attenuation of allodynia in this model
(Meunier et al 2005).
Human clinical studies
Peripheral opioid receptor-mediated analgesia has also been
demonstrated in controlled clinical studies. In experimental
human pain models, administration of the peripherally
restricted opioid agonists morphine-6-glucoronide (M6G)
reduced hyperalgesia induced by freeze lesions and
excessive muscle contraction, which was verified to be via
peripheral action due to the absence of characteristic CNS
effects (Tegeder et al 2003). Patients with chronic
pancreatitis reported reductions in abdominal pain following
intravenous infusion with a peripherally restricted κ-opioid
agonist (Eisenach et al 2003). Similarly, the administration
of locally acting opioids during knee and dental surgery
significantly reduces postoperative pain and recovery time
(Dionne et al 2001; Likar et al 2001; Kalso et al 2002).
Topical application of opioids for the treatment of painful
skin ulcers and oral mucositis has also achieved effective
relief of pain (Twillman et al 1999; Cerchietti et al 2002).Therapeutics and Clinical Risk Management 2005:1(4) 283
Opioid analgesia and inflammation
Separate bioavailability studies indicate that therapeutic
doses of opioids applied topically to skin ulcers are not
readily absorbed into the blood and are therefore likely to
act peripherally (Ribeiro et al 2004). Some clinical studies
assessing the efficacy of locally acting opioids failed to show
an improvement in pain intensity scores, but reported more
subtle modifications such as increases in time to first
analgesic request and a reduction in total analgesic
requirement (Likar et al 2004; Zajaczkowska et al 2004).
Despite overwhelming evidence that peripheral opioid
receptors mediate effective analgesia, there is limited direct
evidence describing opioid mechanisms at peripheral nerve
endings. This is because elucidation of opioid receptor
mechanisms has relied heavily upon techniques that utilize
cultured neurons and other cellular expression systems.
However, experiments in animal models using ion channel
blockers indicate that opioid receptors on peripheral sensory
nerve endings mediate analgesia partly through local
activation of adenosine triphosphate (ATP)-sensitive K
+
channels (Pacheco and Duarte 2005), and inhibition of
L-type Ca2+ channels (Figure 1) (Shimizu et al 2004).
Inflammation promotes opioid receptor
mechanisms in the periphery
An important determination from both animal and human
studies is that peripherally acting exogenous opioids produce
enhanced analgesia in the presence of inflammation. For
example, in the rat paw model, locally acting opioid agonists
significantly increase nociceptive thresholds to mechanical
stimuli in inflamed tissue, but not in noninflamed tissue
(Stein et al 1989; Binder et al 2001). In human studies,
reports from dental surgery patients show that chronically
inflamed tissue exhibits improved analgesic responses
compared with acutely inflamed (Dionne et al 2001) and
noninflamed tissue (Likar et al 2001). These findings
indicate that inflammation promotes opioid receptor
mechanisms in the periphery.
Opioid receptor expression
In primary afferent neurons, opioid receptors are
manufactured in the dorsal root ganglion (DRG) and are
transported both centrally and peripherally by axonal
transport (Hassan et al 1993). In the rat paw model,
Figure 1 Proposed model for opioid receptor-mediated analgesia at peripheral terminals of primary sensory neurons. Activation of opioid receptors by endogenous
or exogenous opioid agonists promotes G-protein coupling. Opioid receptor-coupled G-proteins directly activate inwardly rectifying K+ channels (GIRK+), inhibit
voltage-dependent Ca2+ channels, and inhibit adenylyl cyclase (AC). Opioid receptors indirectly activate phospholipase C (PLC), the mitogen-activated protein kinase
(MAPK) cascade, and large conductance Ca2+-activated K+ channels by utilizing other intermediary messenger systems.Therapeutics and Clinical Risk Management 2005:1(4) 284
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inflammation induces a significant increase in MOR in the
DRG (Ji et al 1995; Zhang et al 1998; Ballet et al 2003;
Zollner et al 2003; Shaqura et al 2004) and in peripheral
nerves innervating the inflamed tissue (Hassan et al 1993;
Mousa et al 2001, 2002). In the spinal cord, there are reports
of either no change (Ballet et al 2003; Shaqura et al 2004),
or increase in MOR expression (Ji et al 1995; Mousa et al
2002); a discrepancy likely due to differences in disease
state and the sensitivity of analytical techniques. Consistent
with increased receptor expression, MOR mRNA levels are
increased in both the DRG (Puehler et al 2004) and in the
spinal cord (Maekawa et al 1996), which supports the thesis
that inflammation increases MOR synthesis. With respect
to DOR and KOR, the effect of inflammation on receptor
expression is less clear in the rat paw model. In separate
studies with similar disease states, DOR expression is
reported to decrease in DRG (Ji et al 1995; Zhang et al 1998),
increase in peripheral tissues (Hassan et al 1993), and both
increase and decrease in the spinal cord (Ji et al 1995; Cahill,
Morinville, et al 2003). DOR mRNA levels reportedly
remain unchanged in the DRG (Puehler et al 2004) and in
the spinal cord (Maekawa et al 1996). In independent
studies, KOR expression has been found to both decrease
and remain static in DRG (Ji et al 1995; Zhang et al 1998),
and remain constant in the spinal cord (Ji et al 1995). A
significant increase in KOR mRNA has been observed in
the spinal cord of animals with peripheral inflammation
(Maekawa et al 1996). Adding further complexity; changes
in KOR and DOR expression have also been reported in
nonneuronal cells. More specifically, the expression of KOR
and DOR have recently been shown to be decreased in the
fibroblast-like synoviocytes of patients with rheumatoid
arthritis and osteoarthritis, particularly where inflammation
was present (Shen et al 2005). Upregulation of the KOR
occurred through exposure to the specific KOR agonist
U69593 (Shen et al 2005), and while these changes occurred
in cells isolated from patients and established in vitro, these
observations could suggest that intra-articular or peripheral
opioids may be useful in the management of these
inflammatory conditions and could have an impact on pain
states in these patients. Despite these apparently conflicting
outcomes, DOR- and KOR-selective opioid agonists deliver
potent antinociception in the inflamed rat paw model,
suggesting the involvement of both DOR and KOR receptors
in pain control during inflammation (Stein et al 1989; Binder
et al 2001; Cahill, Morinville, et al 2003). In a separate
inflammatory model, the inflamed mice intestine, MOR
mRNA, and protein is upregulated in nerves innervating the
gut (Pol et al 2001). Furthermore, intestinal inflammation
significantly increases DOR mRNA in peripheral nerves and
in the spinal cord, and increases DOR and KOR receptor
protein in peripheral nerves (Pol et al 2003).
The mechanisms that affect opioid receptor upregulation
during inflammation are not yet well understood, however,
a number of recent studies provide insight into these
mechanisms. The inflammatory mediator interleukin-6
(IL-6) strongly induces MOR, but not DOR transcription
and translation in the human neuroblastoma cell line SH-
SY5Y (Borner et al 2004). IL-6 evoked increases in MOR
expression are mediated by the transcription factors signal
transducers and activators of transcription 1 (STAT1) and
transcription 3 (STAT3) (Borner et al 2004). In vitro results
with IL-6 are supported by findings that IL-6 knock out
mice have reduced MOR levels in the grey matter of the
midbrain compared with wild type individuals and exhibit
reduced analgesic responses to morphine (Bianchi et al
1999). Interleukin-4 stimulates MOR transcription in
cultured immune cells and cultured neurons via transcription
6 (STAT6) activation of the MOR gene promoter (Kraus et
al 2001). Furthermore, the proinflammatory cytokine tumor
necrosis factor (TNF) induces MOR gene transcription, via
the transcription factor nuclear factor κB (NFκB) in immune
cells (Kraus et al 2003) and neurons (Borner et al 2002).
Nerve growth factor (NGF) is produced by peripheral
tissues, particularly during inflammation (McMahon 1996),
and is implicated in opioid receptor regulation. Transgenic
mice that overexpress NGF show an increase in MOR and
KOR expression and a decrease in DOR expression in DRG
compared with wild type mice, and exhibit increased
nociceptive thresholds (Zwick et al 2003). Further evidence
that NGF influences opioid receptor function is provided
by findings that intrathecal NGF restored opioid
effectiveness in a rat model of neuropathic pain (Cahill,
Dray, et al 2003). In addition to the action of inflammatory
cytokines and growth factors, the increased conduction of
nociceptive signals that occurs during inflammation
promotes opioid receptor transcription in sensory
neurons, particularly during the early stages of inflammation
(Puehler et al 2004). This was evidenced by blocking
neuronal conduction with local anesthetic, which prevented
the upregulation of MOR mRNA in the first 2 hours
following induction of inflammation in the rat hind paw
(Puehler et al 2004).
Opioid receptor efficacy
The ability of opioid agonists to stimulate radiolabelled
Guanosine 5´-Triphosphate (GTP) ([
35S]GTP-γ-S) binding,
provides a measure of Gi/Go-protein coupling efficiency andTherapeutics and Clinical Risk Management 2005:1(4) 285
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the functional status of the opioid receptor (Traynor and
Nahorski 1995). In DRG, but not spinal cord tissue,
(D-Ala, N-Me-Phe, Gly-ol)-Enkephalin (DAMGO)
stimulated (
35S)GTP-γ-S binding is increased in animals
with inflammation (Ballet et al 2003; Zollner et al 2003;
Shaqura et al 2004). These results may simply reflect the
increase in opioid receptor density that occurs in DRG
during inflammation, but nevertheless represent an
improvement in the efficacy of the µ-opioid agonist
DAMGO to stimulate opioid receptor G-protein coupling
and may explain the increased antinociceptive effects of
exogenous opioids in inflammatory conditions (Zollner et
al 2003). Moreover, in cultured sensory neurons, the
expression of MOR mRNA correlates directly with opioid-
evoked inhibition of voltage-gated Ca2+ channels (Silbert
et al 2003), which also suggests that the increase in opioid
receptor expression evident during inflammation translates
into a functional enhancement of opioid efficacy.
Inflammation also alters the subcellular distribution of
opioid receptors, mobilizing receptors towards the cell
membrane (Cahill, Morinville, et al 2003), and disrupts the
perineurial barrier surrounding sensory nerve fibres,
providing opioid peptides better access to cell membrane
receptors (Antonijevic et al 1995). Some inflammatory
chemokines have been reported to desensitize opioid
receptors on peripheral sensory neurons in vitro and to
suppress opioid antinociception to the noninflamed
periaqueductal gray region of the rat brain when
administered before opioid treatment (Szabo et al 2002;
Zhang et al 2004). These findings suggest that elements of
the inflammatory process may, in isolation, impair opioid
efficacy. However, opioids can exert a reciprocal
desensitization of chemokine receptors (Zhang et al 2003),
which is evidence of the complexity of the interaction
between chemokine and opioid receptors; a relationship that
is not fully understood. Furthermore, in the inflamed rat
paw, inflammatory chemokines recruit opioid-containing
polymorphonuclear cells. The blockade of these chemokines
reduces peripheral opioid-mediated antinociception, which
is evidence that chemokines promote opioid mechanisms
(Brack, Rittner, et al 2004b). Tissue acidosis is another
characteristic of inflammation that may affect opioid
efficacy. Interstitial pH as low as 5.6 has been observed in
various inflamed tissues (Edlow and Sheldon 1971; Jacobus
et al 1977; Ward and Steigbigel 1978; Simmen et al 1994;
Andersson et al 1999). In NG108-15 cell membranes, acidic
pretreatment increases opioid receptor-mediated inhibition
of adenylyl cyclase by impairing GTPase activity (Selley et
al 1993). Further evidence that acidic inflammatory pH
improves opioid efficacy is provided by studies using DRG
neurons, which show that morphine inhibition of Ca
2+
transients is enhanced at low extracellular pH (Kapitzke et
al 2005).
Taken together, the changes that occur during inflam-
mation contribute to enhanced opioid receptor expression
and efficacy, particularly for MOR.
Immune cells contain opioid
peptides
Endogenous opioid peptides
In mammals, pro-opiomelanocortin (POMC), pro-
enkephalin (PENK) and pro-dynorphin (PDYN) are the
precursor proteins from which the main endogenous opioid
peptides β-endorphin (END), met-enkephalin (ENK), and
dynorphin-A (DYN), respectively, are derived (Nakanishi
et al 1979; Kakidani et al 1982; Noda et al 1982). Dynorphin
A and B, which are derived from PDYN, have relatively
high affinity for KOR, but also some affinity for MOR and
DOR. ENK and leu-enkephalin are endogenous ligands
derived from PENK that display preferential binding to
DOR, lower affinity for MOR, and negligible binding to
KOR (Przewlocki and Przewlocka 2001). END, along with
several nonopioid peptides, is derived from the precursor
protein POMC and exhibits equipotent MOR and DOR
binding while having lower affinity for KOR (Akil et al 1981;
Przewlocki and Przewlocka 2001). Endomorphin-1 and
endomorphin-2 are MOR-selective endogenous peptides of
so far unknown origin that have been found in distinct
regions of rat brain as well as primary neurons and the spinal
cord (Martin-Schild et al 1997; Zadina et al 1997; Schulz et
al 1998)
Opioid peptides in nonneuronal cells
The role of END, ENK, and DYN has been described in
detail for both central and peripheral antinociceptive
pathways (Przewlocki and Przewlocka 2001). Interestingly,
nonneuronal tissues have also been described to contain
opioid peptides that may contribute to peripheral
antinociception.(Cabot et al 1997, 2001; Schafer et al 1994;
Finegold et al 1999; Lin et al 2002; Mousa et al 2004).
Opioid peptides have been shown to be expressed in
keratinocytes (Khodorova et al 2003), and it has been
suggested that these cells may be an important source of
endogenous opioid receptor agonists. In particular, activation
of both the endothelin-B and cannabinoid CB2 receptorsTherapeutics and Clinical Risk Management 2005:1(4) 286
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have been shown to elicit analgesia in vivo through release
of END from keratinocytes (Khodorova et al 2003; Ibrahim
et al 2005) This occurred in models where pain was induced
either through injection of endothelin-1, or a noxious thermal
stimulus, and may highlight that local release of opioid
peptides can achieve anatomically specific analgesia
(Khodorova et al 2003; Ibrahim et al 2005) .
Immune cells are of particular interest with respect to
nonneuronal cell types involved in endogenous analgesic
mechanisms. Expression of opioid peptides by immune cells
have been extensively studied and have been shown to
express both full-length and truncated mRNA encoding for
the precursor proteins POMC, PENK, and PDYN. Moreover,
the respective opioid peptides END, ENK, and DYN have
been described in many immune cells of rodent and human
origin (Lolait et al 1986; Smith et al 1986; Zurawski et al
1986; Oates et al 1988; Buzzetti et al 1989; Rosen et al
1989; Stein, Hassan, et al 1990; Hassan et al 1992;
Przewlocki et al 1992; van Woudenberg et al 1992; Schafer
et al 1994; Linner et al 1996; Cabot et al 1997, 2001; Lyons
and Blalock 1997; Kamphuis et al 1998; Blalock 1999;
Binder et al 2004; Mousa et al 2004). Originally, the role of
these opioid peptides was thought to consist of the regulation
of local immune function through the neuroendocrine axis
(Lolait et al 1986; Oates et al 1988; Rosen et al 1989;
Manfredi et al 1995; Kamphuis et al 1998; Blalock 1999).
This was supported by the observation that immune cells
express opioid receptors (Carr et al 1989). In addition,
functional evidence verified that opioids can modulate
immune function, including mitogen-induced proliferation,
antibody production, and natural killer (NK) activity
(Manfredi et al 1995). An additional role for these peptides
emerged with the observation that opioid peptides released
locally from immune cells can act on opioid receptors
expressed on peripheral neurons to exert an antihyperalgesic
effect in inflamed tissue (Stein, Hassan, et al 1990; Schafer
et al 1994, 1996; Cabot et al 1997, 2001; Cabot 2001;
Mousa et al 2001, 2004; Rittner et al 2001; Rittner and
Stein 2005).
Immune cells express opioid peptides
and their precursor proteins
The mechanism proposed for this immune-derived
peripheral antinociception involves recruitment of immune
cells to local inflamed areas, where they release endogenous
opioid peptides upon stimulation with proinflammatory
mediators such as interleukin 1β (IL-1β) and corticotrophin-
releasing factor (CRF) as well as sympathetic mediators such
as noradrenaline (Stein, Hassan, et al 1990; Schafer et al
1994, 1996; Cabot et al 1997, 2001; Cabot 2001; Mousa et
al 2001, 2004; Rittner et al 2001; Binder et al 2004; Rittner
and Stein 2005). Numerous leukocytes, including
lymphocytes, macrophages, monocytes, and human
peripheral blood mononuclear cells, have been reported to
contain these opioid peptides (Lolait et al 1986; Smith et al
1986; Zurawski et al 1986; Oates et al 1988; Buzzetti et al
1989; Rosen et al 1989; Stein, Hassan, et al 1990; Hassan
et al 1992; Przewlocki et al 1992; van Woudenberg et al
1992; Schafer et al 1994; Linner et al 1996; Cabot et al
1997, 2001; Lyons and Blalock 1997; Kamphuis et al 1998;
Blalock 1999; Binder et al 2004; Mousa et al 2004).
Generally, both precursor protein as well as opioid peptide
expression appear to be increased in immune cells from
inflamed tissue or mitogen-stimulated cells compared with
quiescent leukocytes (Smith et al 1986; Zurawski et al 1986;
Buzzetti et al 1989; Rosen et al 1989; Hassan et al 1992;
van Woudenberg et al 1992; Cabot et al 1997, 2001; Lyons
and Blalock 1997; Mousa et al 2004). Regulation of POMC
in lymphocytes has been reported to be dynamic with both
mRNA and opioid peptide levels increased in mitogen-
stimulated cells, while POMC expression in macrophages
was of a more constitutive nature (Lyons and Blalock 1997).
In addition, the predominant opioid-containing cell type
appears to be dynamically regulated depending on the
progression of the inflammatory cascade (Rittner et al 2001).
Increased complexity is additionally suggested by an
observation that immune cells from inflamed lymph nodes
contain relatively less opioid peptides compared with cells
from noninflamed lymphatic tissue, while at the same time
opioid peptide content in local inflamed tissue is increased
(Cabot et al 1997). This observation is consistent with a
model of peripheral opioid antinociception whereby immune
cells migrate to inflamed tissue in a site directed manner,
release these opioid peptides, and then return to lymphatic
tissues depleted of peptide (Figure 2) (Cabot et al 1997).
Opioid peptides involved in peripheral
antinociception
END and ENK have been proposed to be the most important
opioid peptides involved in immune-derived opioid
antinociception. Antibodies to both END and ENK could
reverse the antihyperalgesic effect observed after release of
these peptides from immune cells was stimulated using CRF
or IL-1β (Stein, Hassan, et al 1990; Cabot et al 2001).
Although DYN and PDYN levels were generally reported
to be low, this opioid peptide is likely to be of someTherapeutics and Clinical Risk Management 2005:1(4) 287
Opioid analgesia and inflammation
significance in mediating peripheral antinociception as
antiDYN has been reported to inhibit IL-1β-induced
analgesia (Przewlocki et al 1992; Cabot et al 2001). In
addition, expression of both the opioid peptide and its
precursor were observed to be increased significantly in
immune cells during inflammation, although absolute levels
were low (Cabot et al 2001). The exact role of DYN in
peripheral antinociception remains to be elucidated.
All three opioid peptides have been proposed to be
contained within vesicular structures similar to those
observed in neurons. The release of these endogenous opioid
receptor ligands is Ca
2+ dependent and can be evoked by
stimulation with high K+ (Manfredi et al 1995; Cabot et al
1997, 2001). Ultrastructural studies have confirmed the
presence of END in secretory granules in macrophages,
monocytes, granulocytes, and lymphocytes within immune
cells from inflamed tissue (Mousa et al 2004). These
granules were grouped in small vesicular structures within
the cytoplasm, while larger vesicles were observed to
possess extended processes ready for exocytosis (Mousa et
al 2004).
Numerous papers have reported that immune cells
contain opioid peptides and increasing functional evidence
is being accumulated to suggest that these endogenous
opioid receptor ligands can be released in local inflamed
tissues by leukocytes to alleviate inflammatory hyperalgesia
(Lolait et al 1986; Cabot et al 1997; Kamphuis et al 1998;
Binder et al 2004; Mousa et al 2004). In early inflammation,
the degree of antinociception evoked through these locally
released opioid peptides relies heavily upon the number of
opioid receptors expressed in these tissues rather than the
number of opioid peptide-containing immune cells recruited
to the inflamed site (Brack, Rittner, et al 2004c). Analgesia,
mediated through the release of endogenous opioid peptides,
may become increasingly important as the number of opioid
receptors expressed increases with the progression of
inflammation (Zollner et al 2003; Brack, Rittner, et al 2004c).
Inflammation and the migration of
circulating leukocytes
Leukocyte migration and adhesion
molecules
For opioid-containing immune cells to elicit antinociception
by releasing their endogenous opioid peptide load in local
inflamed tissue, these cells must first migrate to these tissues.
Figure 2 Endogenous opioid peptides are released by immune cells to reduce inflammatory pain. Adhesion molecules expressed on immune cells and inflamed
endothelium coordinate the migration of circulation immune cells into inflamed tissue. The proinflammatory mediators corticotropin-releasing factor (CRF) and
interleukin-1β (IL-1β), as well as the sympathetic neurotransmitter, noradrenaline, stimulate immune cells to secrete their opioid peptides. These peptides activate
opioid receptors located on the peripheral ends of sensory neurons and effectively reduce inflammatory pain. Immune cells, devoid of their opioid contents, then
continue their passage to neighbouring lymph nodes.Therapeutics and Clinical Risk Management 2005:1(4) 288
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“Homing” of immune cells to inflamed sites is a complex
process and involves numerous inflammatory mediators,
chemoattractants, and adhesion molecules. The extra-
vasation of leukocytes into inflamed tissue is enabled by
the interaction of adhesion molecules expressed on
leukocytes and vascular endothelium. These adhesion
molecules comprise the carbohydrate binding selectins,
immunoglobulins (Ig) such as ICAM and PECAM, and the
integrin family of α and β subunit heterodimers (Wahl et al
1996). The upregulation of adhesion molecules and the
engagement of leukocytes in the extravasation process are
promoted by various inflammatory mediators and
chemoattractants such as interleukin-1 (IL-1), interleukin-8
(IL-8), tumor necrosis factor-α (TNF-α), interferon-γ
(IFN-γ), thrombin, histamine, RANTES (Regulated upon
Activation Normal T cell Expressed and Secreted),
monocyte chemotactic peptide (MCP), and macrophage
inflammatory peptides (MIP) (Springer 1994; Wahl et al
1996; Villarreal et al 2001). Passing leukocytes are initially
tethered by the action of selectins. P- and E-selectins are
expressed on vascular endothelium and L-selectins are
constitutively expressed on leucocytes (Brown 1997). Once
loosely tethered by selectins, leukocytes roll along the
inflamed endothelium, which promotes the upregulation of
leukocyte integrins and further adhesion (Springer 1994;
Butcher and Picker 1996). Leukocyte integrins bind to the
immunoglobulins expressed on endothelium; a firm
interaction that results in the arrest of circulating leukocytes
(Springer 1994; Butcher and Picker 1996). Leukocyte arrest
is followed by diapedesis of the leukocyte, through relaxed
endothelial junctions and into the inflamed tissue. These
processes enable a targeted and leukocyte subset selective
migration at the site of inflammation (Springer 1994;
Butcher and Picker 1996).
Presentation of opioid-containing
immune cells in inflamed tissue
In the rat paw model, the induction of inflammation with
FCA results in a significant increase in opioid-expressing
leukocytes in the inflamed tissue (Cabot et al 1997; Rittner
et al 2001). Assessment with fluorescence-activated cell
staining indicates that approximately 20% of immune cells
that infiltrate inflamed tissue contain endogenous opioid
peptides (Rittner et al 2001; Machelska et al 2002). At the
early stages of inflammation, opioid-expressing immune
cells are predominantly from a neutrophil lineage,
representing 66% of opioid-containing cells. At later stages,
monocytes and macrophages are prominent, representing
73% of opioid-expressing leukocytes (Rittner et al 2001;
Schmitt et al 2003). Other studies have shown that activated
lymphocytes are the prevalent opioid-containing immune
cell type in the later stages of inflammation (Cabot et al
1997; Mousa et al 2001). This discrepancy is likely due to
the use of different immunoreactive staining procedures.
Opioid-expressing cells roughly reflect general immune cell
type representation at different stages of inflammation
(Rittner et al 2001).
Immune-derived opioids reduce
inflammatory pain
Stress-induced analgesia during
inflammation in peripheral tissue
Stressful stimuli trigger potent analgesia mediated by
endogenous opioid systems in the CNS (Yamada and
Nabeshima 1995). The response to stress is characterized
by stimulation of the hypothalamic–pituitary–adrenocortical
axis resulting in the sequential secretion of CRF and
adrenocorticotrophic hormone (ACTH); activation of the
sympathetic nervous system, which releases noradrenaline
from the adrenal medulla and sympathetic nerve endings;
and the activation of endogenous opioid systems in the CNS
(Yamada and Nabeshima 1995). In rats with inflammation
of the hind paw however, stress-induced analgesia is
mediated predominantly by endogenous opioids that bind
to peripheral opioid receptors to effectively reduce
inflammatory pain (Stein, Gramsch, et al 1990).
A common technique for evoking stress-induced
analgesia is cold water swim stress (CWS). In the rat paw
model, CWS induces sudden antinociception that manifests
as significant increases in pain thresholds in the inflamed
paw (Stein, Gramsch, et al 1990). This analgesia is most
potent immediately following the insult and subsides within
10 to 15 minutes (Stein, Gramsch, et al 1990). The
antinociceptive effect of CWS is dose-dependently
reversible by opioid receptor antagonists, which suggests
that antinociception is opioid receptor-mediated. At the early
stages of inflammation (6 hours after induction with FCA),
CWS-evoked antinociception is completely blocked by
systemically acting doses of naloxone and partially blocked
by peripherally selective antagonists, which demonstrates
a central and peripheral component (Machelska et al 2003).
However, as inflammation becomes chronic (described in
this study as 4 days post FCA), peripherally selective
antagonists completely abolish CWS-evoked anti-Therapeutics and Clinical Risk Management 2005:1(4) 289
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nociception, indicating that analgesia is mediated
exclusively by opioid receptors on peripheral sensory nerves
innervating the inflamed paw (Machelska et al 2003). The
use of antibodies against specific endogenous opioid
peptides and selective opioid receptor antagonists reveal that
at the early stages of inflammation, the peripheral
component of CWS-evoked analgesia is mediated by END,
ENK, and DYN, which activate MOR, DOR, and KOR
(Machelska et al 2003). At later stages of inflammation (as
observed at 4 days post FCA), antinociception is delivered
wholly by END, activating peripheral MOR and DOR (Stein,
Gramsch, et al 1990; Machelska et al 2003).
Endogenous opioids are released from
leukocytes
CWS-evoked analgesia in the rat paw depends on the local
action of CRF and noradrenaline, evidenced by reversal
following local injection of CRF receptor antagonists and
adrenergic receptor antagonists respectively (Schafer et al
1996; Binder et al 2004). CRF, noradrenaline, and the
proinflammatory cytokine, IL-1β, evoke the release of
opioid peptides from leukocytes. Immune cell suspensions
extracted from rats with inflamed hind paws exhibit receptor-
specific and concentration-dependent opioid release when
exposed to CRF, noradrenaline, and IL-1β (Schafer et al
1996; Cabot et al 1997, 2001; Binder et al 2004; Mousa et
al 2004). CRF induces the release of END, ENK, and DYN
(Cabot et al 2001); noradrenaline releases END (Binder et
al 2004; Mousa et al 2004); and IL-1β releases END and
DYN (Cabot et al 2001). An upregulation of receptors for
these mediators on immune cells participating in an
inflammatory response indicating that inflammation
consolidates opioid release mechanisms (Zoukos et al 1994;
Mousa et al 1996). Separate administration of CRF,
noradrenaline, and IL-1β to the inflamed rat paw evokes
potent dose-dependent and pharmacologically reversible
analgesia (Binder et al 2004; Schafer et al 1994). This
antinociceptive effect is the result of local action at the
inflamed site as equivalent doses administered systemically
are ineffective (Schafer et al 1994; Binder et al 2004).
Antibodies against opioid peptides and opioid receptor
antagonists abolish the analgesic effects of CRF,
noradrenaline, and IL-1β, confirming that the observed
analgesia is mediated by endogenous opioids that activate
opioid receptors (Figure 2) (Schafer et al 1994; Binder et al
2004). Further evidence supporting immune cells as the
source of opioid peptides is provided by findings that the
administration of CRF, noradrenaline, and IL-1β into
noninflamed paws does not evoke an antinociceptive effect
(Schafer et al 1994; Binder et al 2004). The degree of
analgesia induced by exposure to CWS increases
proportionally with the presentation of opioid-containing
immune cells in the inflamed hind paw (Rittner et al 2001;
Machelska et al 2003).
Impaired immune cell function
leads to impaired endogenous
analgesia
Numerous studies have reported that impaired immune cell
function is associated with diminished opioid analgesia,
which is consistent with the model where immune cells
release opioid peptides in inflamed tissue to elicit
antinociception (Stein, Hassan, et al 1990; Przewlocki et al
1992; Schafer et al 1994; Machelska et al 1998, 2003; Mousa
et al 2000; Brack et al 2004, 2004a, 2004b; Hermanussen
et al 2004). This effect has been described for immuno-
modulatory agents that affect immune cell trafficking as well
as numerous treatments that compromise the functional
integrity of leukocytes (Stein, Hassan, et al 1990; Przewlocki
et al 1992; Schafer et al 1994; Machelska et al 1998, 2003;
Mousa et al 2000; Brack et al 2004, 2004a, 2004b;
Hermanussen et al 2004).
Immune cell trafficking
Fucoidin, which binds to selectins and blocks leukocyte
“rolling”, has been reported to impair analgesia induced by
CWS and CRF (Machelska et al 1998). This impaired
antinociception was paralleled by a decrease in END content
as well as a decrease in the number of END-containing
immune cells in inflamed tissue (Machelska et al 1998).
Similarly, intracellular adhesion molecule-1 (ICAM-1) has
been found to be upregulated in inflamed tissue and appears
to contribute to the recruitment of opioid-containing cells
to these local microenvironments as antiICAM-1 decreased
CWS- and CRF-induced analgesia (Machelska et al 2002).
Other adhesion molecules, including P-selectin, platelet-
endothelial adhesion molecule-1 (PECAM-1), and
L-selectin, are also upregulated in inflammation, and these
increased expression levels correlate with increased END
levels (Mousa et al 2000). However, while the exact role of
these adhesion molecules in endogenous opioid analgesia
remains to be elucidated, results indicate that PECAM-1 is
not required for endogenous opioid analgesia (Machelska
et al 2004). The same study confirmed functional integrityTherapeutics and Clinical Risk Management 2005:1(4) 290
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of selectins and integrins as essential for immune-derived
antinociception (Machelska et al 2004).
In contrast to adhesion molecule-mediated leukocyte
trafficking, chemokine-mediated recruitment of poly-
morphonuclear cells may target opioid-containing
leukocytes more specifically, as immune cells containing
opioid peptides have been reported to be mostly chemokine
receptor (CXCR2)-positive (Brack, Rittner, et al 2004b).
Accordingly, a blockade of the keratinocyte-derived
chemokine (KC) and macrophage inflammatory protein-2
(MIP-2) decreased the number of opioid-containing
leukocytes in inflamed tissue and abolished CRF-induced
antinociception in the inflamed rat paw (Brack, Rittner, et
al 2004b).
Effect of immunosuppressants on
immune-derived antinociception
Further evidence for the importance of the functional
integrity of opioid-containing immune cells in endogenous
analgesia stems from the observation that the immuno-
suppressant Cyclosporine A (CsA) can dose-dependently
block CWS-, IL-1- and CRF-induced peripheral analgesia
(Stein, Hassan, et al 1990; Schafer et al 1994; Hermanussen
et al 2004). The reduced paw pressure threshold that has
been observed in inflamed paws of CsA-treated animals was
mirrored by a decrease in the number of infiltrating
lymphocytes and could be reversed by administration of
activated lymphocytes (Hermanussen et al 2004).
Nonspecific immunosuppression induced by whole body
irradiation also decreased stress-induced antinociception in
inflamed paws, while more specific depletion of monocytes/
macrophages by liposomal clodronate similarly decreased
stress-induced endogenous opioid antinociception without
affecting exogenous opioid analgesia (Przewlocki et al 1992;
Brack et al 2004).
Clinical evidence for association
between impaired immune function and
increased pain
Reduced END content in immune cells has clinically been
reported in numerous painful conditions, including arthritis,
Crohn’s disease, fibromyalgia, migraine, and tension
headache (Wiedermann et al 1992, 1994; Panerai et al 2002).
There is little evidence to suggest that opioid content in
circulating immune cells significantly contributes to
analgesia. A reduction in opioid content of these cells may
compromise the local delivery of opioid peptides to inflamed
tissues by migrating immune cells and thus impair
endogenous analgesic mechanisms in these patients. In line
with this observation, pain associated with disease or
inflammation may be increased in immunocompromised
patients (Merine et al 1987). A positive correlation between
immunosuppression and increased pain has been reported,
and in AIDS patients in particular, a decreased CD4+ count
appears to be a risk factor for developing painful pathologies
such as polyneuropathy (Lebovits et al 1994; Wyatt and
Fishman 1994; Lefkowitz 1996; Hewitt et al 1997; Schifitto
et al 2002). These observations highlight the importance of
the immune system and release of endogenous opioid
peptides for antinociception.
Immunosuppressive effects of
exogenous opioids
Exogenous opioids such as morphine remain the most
effective treatment for acute and chronic pain. There is
evidence suggesting that opioids have an immuno-
suppressive action as well as clinically apparent side effects,
such as respiratory depression, constipation, tolerance, and
dependence (Risdahl et al 1998). The implications of opioid-
evoked immunosuppression are particularly relevant during
the postoperative period when pain and susceptibility to
infection are high; for sufferers of chronic pain and drug
users who administer opioids for extended periods; and for
patients with immunosuppressive disease such as AIDS,
transplant patients, and the elderly, who are predisposed to
opportunistic infections.
Evidence for opioid-evoked
immunosuppression
Much of the data that suggests opioids have
immunosuppressive effects come from epidemiological
studies with drug users. These individuals are reported to
have markedly increased incidence of skin and soft tissue
infections, pulmonary infections, endocarditis, skeletal
infections, malaria, and viral hepatitis, although it is accepted
that interpretation of these findings is confounded by
compromised lifestyle practices associated with this
population (Hussey and Katz 1950; Scheidegger and
Zimmerli 1989; Risdahl et al 1998). In healthy nonaddicted
individuals, morphine treatment for obstetric procedures
resulted in the reactivation of herpes simplex virus (Crone
et al 1988), supporting an immunosuppressive action.
Animal models of opioid administration and infection show
increased mortality rates in opioid treated animals withTherapeutics and Clinical Risk Management 2005:1(4) 291
Opioid analgesia and inflammation
experimentally-induced sepsis and Toxoplasma gondii
infection, reversible by opioid receptor antagonists (Chao
et al 1990; Roy et al 1999). Morphine-dependent swine,
challenged with herpes virus, exhibited enhanced
pneumonia secondary to herpes virus infection, although
these animals also exhibited a paradoxical decrease in
clinical signs associated with neurological disease (Risdahl
et al 1993). In mice inoculated with Streptococcus
pneumonia, chronic morphine treatment delayed neutrophil
recruitment, increased bacterial burden, and increased
mortality (Wang et al 2005). Various commonly measured
immune parameters are significantly suppressed following
opioid exposure in drug users, healthy human subjects, and
animal models. These include suppressed NK cell activity
(Carr et al 1993; Yeager et al 1995; Sacerdote et al 1997),
macrophage phagocytic function (Rojavin et al 1993),
cytokine production (Bhargava et al 1994; Sacerdote et al
1997), lymphocyte proliferation (Bhargava et al 1994;
Sacerdote et al 1997), and spleen and thymus weight and
cellularities (Fuchs and Pruett 1993; Bhargava et al 1994).
In experiments with opioid receptor knock out mice, mutant
mice did not exhibit the abnormal immune parameters that
were observed in wild type mice following chronic morphine
treatment, indicating that opioid receptors mediate
morphine-induced immunosuppression (Gaveriaux-Ruff et
al 1998). These findings collectively indicate that exposure
to exogenous opioids impairs resistance to infection and
suppresses immune function.
Centrally mediated opioid-evoked
immunosuppression
There is evidence that opioid-evoked immunosuppression
is mediated by opioid receptors in the CNS. Systemic
administration of morphine significantly reduced
lymphocyte proliferation ex vivo but the peripherally
restricted N-methylmorphine did not, suggesting that a
central mechanism mediates immunosuppression
(Hernandez et al 1993). Furthermore, the central
administration of both morphine and N-methylmorphine
effectively inhibited lymphocyte proliferation. Several
studies have identified the periaqueductal gray (PAG) matter
of the mesencephalon as a site of morphine-induced opioid
receptor-mediated immunosuppression. Injection of
morphine into the PAG is reported to suppress ex vivo
macrophage nitric oxide (NO) production, NK cell activity,
lymphocyte proliferation, and leukocyte IL-2 production
(Gomez-Flores et al 1999; Gomez-Flores and Weber 1999).
In rats with FCA-induced inflammation of the hind paw,
concomitant intrathecal morphine administration selectively
attenuated the presentation of END-positive leukocytes in
the inflamed paw without affecting total immune cell
numbers (Schmitt et al 2003). This result led to the
hypothesis that arresting pain transmission in the CNS
signals a reduced need for immune-derived opioid peptides
in the inflamed tissue (Schmitt et al 2003), and provides
further evidence for centrally mediated opioid immuno-
modulation.
Opioids activate receptors on immune
cells and suppress immune activity
In addition to centrally-mediated immunosuppression, the
expression of opioid receptors on immune cells suggest that
opioids may modulate immune function by direct action on
these cells (Bidlack 2000). This is supported by findings
that in vitro exposure to morphine resulted in concentration-
dependent and antagonist-reversible inhibition of
macrophage phagocytic function (Rojavin et al 1993.
Opioids also directly suppress macrophage production of
proinflammatory cytokines IL-1, IL-6, TNF-α (Alicea et al
1996), and impair monocyte chemotaxis in response to
cytokines MIP-1α, MCP-1, and RANTES, through opioid
receptor-mediated heterologous desensitization of
chemokine receptors (Grimm et al 1998). Morphine directly
upregulates immune cell Fas receptors that trigger apoptosis
of the cell when activated by the ligand FasL (Yin et al 1999).
In this way, morphine administered in vivo apparently
primes leukocytes for elimination by apoptosis and
suppresses the immune response (Yin et al 1999).
Opioid stimulation of immune cell
function
In contrast to findings that opioids exert an immuno-
suppressive action, there is evidence that some opioids,
particularly endogenous opioid peptides, stimulate aspects
of immune function. In vitro experiments demonstrate that
endogenous opioids such as END and ENK enhance human
NK cell activity (Mathews et al 1983); increase IL-2
production in the lymphoid cell line EL-4 (Bessler et al
1990); increase leukocyte surface expression of compliment
and immunoglobulin receptors (Menzebach et al 2003);
increase leukocyte oxidative burst activity (Menzebach et
al 2003); and augment macrophage tumoricidal activity
(Hagi et al 1994). In vivo administration of ENK reportedly
improves the survival rate of mice infected with herpes
simplex virus and inhibits tumor growth (Faith et al 1987).Therapeutics and Clinical Risk Management 2005:1(4) 292
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The immunostimulatory properties of endogenous opioids
suggest that their release by immune cells in inflamed tissue
not only controls pain but also stimulates immune function.
Clinical implications for pain
control
Systemic administration of opioids is clinically associated
with numerous side effects. While immunomodulatory
effects of opioids can have clinical implications as described
above, most dose-limiting adverse events, such as respiratory
depression, sedation, and tolerance are mediated through
activation of central opioid receptors (Kieffer and
Gaveriaux-Ruff 2002). A logical consequence is the attempt
to target peripheral opioid receptors more specifically.
Numerous studies have demonstrated that peripheral opioids
can provide effective analgesia (Stein et al 1989; Likar et al
2001; Truong et al 2003; Furst et al 2005; Pacheco and
Duarte 2005). The immunosuppressive effect of opioid
receptor agonists may contribute to peripheral opioid
analgesia as it has been speculated that a local anti-
inflammatory effect contributed to prolonged analgesia
produced by intra-articular morphine (Stein et al 1999).
Strategies to target peripheral opioid receptors
specifically include the development and use of peripherally
active opioid receptor agonists, such as loperamide,
asimadoline, and frakefamide, which can usually penetrate
the blood brain barrier poorly, or local administration of
centrally active opioids as well as treatments aimed at
reducing degradation of locally released peptides (Barber
et al 1994; DeHaven-Hudkins et al 1999; Chen et al 2001;
Zajaczkowska et al 2004; Modalen et al 2005). Peripherally
selective opioids have met with some clinical success,
although most work has been carried out with peripherally
selective KOR agonists such as fedotozine (Delvaux 2001).
Despite promising pilot studies, both centrally mediated
adverse events as well as peripheral side effects arising from
systemic administration of opioid agonists, including
constipation, could not be completely excluded (Delvaux
2001; Eisenach et al 2003; Riviere 2004). Thus, research
aimed at the development of opioid receptor agonists that
do not cross the blood brain barrier and are peripherally
selective, but can be administered orally to achieve
peripheral opioid analgesia remains ongoing. Targeted
delivery of opioids locally to the site of pain could avoid
the problems of peripherally selective opioid receptor
agonists which retain the potential to cause side effects
mediated through opioid receptor activation in the periphery.
Side effects include nausea and vomiting arising from
stimulation of opioid receptors in the chemo-receptor trigger
zone, and constipation from opioid modulation of GI
function. Accordingly, while local administration of
centrally active opioid receptor agonists can be effective,
limiting factors are problems arising from the required routes
of administration, such as intra-articular injection (Kizilkaya
et al 2004).
Historically, immunosuppression has been used as an
analgesic strategy in numerous inflammatory conditions
such as rheumatoid arthritis (Lipsky 1983). In light of recent
evidence suggesting that endogenous opioid peptides are
released locally from immune cells to elicit antihyperalgesia
(Stein, Hassan, et al 1990), current clinical practices are
likely to be challenged as our understanding of the complex
interaction between the immune system and pain control
increases. The role of the immune system in analgesia is
likely to be delicately balanced depending on whether
infiltrating cells are proinflammatory and proalgesic or their
major role is an antiinflammatory and analgesic one. In
situations where endogenous antinociception exceeds
hyperalgesia mediated by immune cells, immuno-
suppression of modulation of immune cell trafficking might
increase pain. This hypothesis is supported by the
observation that intra-articular naloxone lead to an increase
in postoperative pain and analgesic consumption (Stein et
al 1993).
Approaches could target immune cell trafficking to
increase immune-mediated endogenous opioid anti-
nociception and thus achieve analgesia, which lacks the side
effects usually associated with systemic administration of
opioid receptor agonists. The immigration of opioid-
containing immune cells could be specifically encouraged
by utilising chemokines or adhesion molecules. An increase
in antinociceptive and decrease in proalgesic cell migration
would complement current immunosuppressive treatment
strategies. Endogenous opioid analgesia could be further
enhanced by increasing infiltrating analgesic cell numbers
or by increasing opioid peptide production in these cells.
While stimulation of immune cell production using
granulocyte colony-stimulating factor (G-CSF) and stem cell
factor (SCF) has not met with the expected increase in
endogenous analgesia to date, gene therapy targeting
endogenous opioid peptide production in peripheral neurons
has had some success and may be applied to opioid-peptide
containing immune cells in future (Braz et al 2001; Brack,
Rittner, et al 2004a; Duplan et al 2004; Chuang et al 2005).
A further approach to enhance peripheral opioid
analgesia includes inhibition of degradation of endogenousTherapeutics and Clinical Risk Management 2005:1(4) 293
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opioid peptides. Using this approach, enhanced anti-
nociception was achieved in a rodent model of thermal pain
by administration of enkephalin-degrading enzyme inhibitor
prodrugs (Chen et al 2001). In addition to enhanced
antinociception, an additional benefit of this approach to
achieve analgesia is the relative lack of immunosuppressive
effects of endogenous opioid peptides, which would render
these compounds superior to exogenous opioids in certain
patient groups. Accordingly, modifications that would enable
dosing with these endogenous peptides by eliminating
instability and poor bioavailability of the compounds could
be the beginning of a new class of analgesic opioid agonists
(Dhanasekaran et al 2005)
The clinical implications of the complex interactions
between the immune system and pain control are especially
pertinent to immunocompromised patients. An impairment
in immune cell function may lead to decreased endogenous
antinociception and thus increased pain (Merine et al 1987).
In AIDS patients in particular, undertreatment of pain has
been reported to be common (Lebovits et al 1994), which
gives greater significance to our understanding of how
endogenous opioid antinociception might be altered in
immunocompromised patient groups. Future studies
directed at investigating changes in immune cell trafficking
and endogenous opioid analgesia in these patients may
provide clinical strategies to more effectively treat pain.
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